These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 2866563)

  • 21. Neuroendocrine effects of apomorphine in chronic schizophrenic patients under long-term neuroleptic therapy and after drug withdrawal: relations to psychopathology and tardive dyskinesia.
    Müller-Spahn F; Ackenheil M; Albus M; May G; Naber D; Welter D; Zander K
    Psychopharmacology (Berl); 1984; 84(3):436-40. PubMed ID: 6151210
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Apomorphine does not lower the concentration of homovanillic acid in the plasma of normal humans.
    Scheinin M
    Psychopharmacol Bull; 1984; 20(4):660-6. PubMed ID: 6494391
    [No Abstract]   [Full Text] [Related]  

  • 23. Dopaminergic responsivity during cocaine abstinence: a pilot study.
    McDougle CJ; Price LH; Palumbo JM; Kosten TR; Heninger GR; Kleber HD
    Psychiatry Res; 1992 Jul; 43(1):77-85. PubMed ID: 1359594
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Schneider's first-rank symptoms of schizophrenia. An association with increased growth hormone response to apomorphine.
    Whalley LJ; Christie JE; Brown S; Arbuthnott GW
    Arch Gen Psychiatry; 1984 Nov; 41(11):1040-3. PubMed ID: 6497565
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Apomorphine has no effect on plasma homovanillic acid in schizophrenic patients.
    Davidson M; Kendler KS; Davis BM; Horvath TB; Mohs RC; Davis KL
    Psychiatry Res; 1985 Oct; 16(2):95-9. PubMed ID: 3865258
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Neuroendocrinology and schizophrenia research].
    Müller-Spahn F
    Monogr Gesamtgeb Psychiatr Psychiatry Ser; 1991; 64():1-96. PubMed ID: 1682802
    [No Abstract]   [Full Text] [Related]  

  • 27. Pharmacological effects of methylphenidate on plasma homovanillic acid and growth hormone.
    Sharma RP; Javaid JI; Pandey GN; Easton M; Davis JM
    Psychiatry Res; 1990 Apr; 32(1):9-17. PubMed ID: 2190251
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Longitudinal changes in symptoms and plasma homovanillic acid levels in chronically medicated schizophrenic patients.
    Suzuki E; Kanba S; Nibuya M; Adachi S; Sekiya U; Shintani F; Kinoshita N; Yagi G; Asai M
    Biol Psychiatry; 1994 Nov; 36(10):654-61. PubMed ID: 7880934
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Suppression of prolactin by dopamine agonists in schizophrenics and controls.
    Rotrosen J; Angrist B; Clark C; Gershon S; Halpers FS; Sachar EJ
    Am J Psychiatry; 1978 Aug; 135(8):949-51. PubMed ID: 665840
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neuroendocrinological and biochemical effects of chronic neuroleptic treatment.
    Hippius H; Ackenheil M; Müller-Spahn F
    Adv Biochem Psychopharmacol; 1985; 40():9-13. PubMed ID: 2862769
    [No Abstract]   [Full Text] [Related]  

  • 31. Effect of naloxone or levallorphan on serum prolactin concentrations and apomorphine-induced growth hormone secretion.
    Lal S; Nair NP; Cervantes P; Pulman J; Guyda H
    Acta Psychiatr Scand; 1979 Feb; 59(2):173-9. PubMed ID: 420037
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of metabolic perturbation on plasma homovanillic acid in schizophrenia. Relationship to prefrontal cortex volume.
    Breier A; Davis OR; Buchanan RW; Moricle LA; Munson RC
    Arch Gen Psychiatry; 1993 Jul; 50(7):541-50. PubMed ID: 8317948
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multihormonal responses to apomorphine in mental illness.
    Mokrani MC; Duval F; Crocq MA; Bailey PE; Macher JP
    Psychoneuroendocrinology; 1995; 20(4):365-75. PubMed ID: 8532820
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Noradrenergic and dopaminergic interrelation in schizophrenia.
    Brambilla F; Marini S; Saito A; Fassone G; Picardi A; Nerozzi D; Pancheri P
    Psychiatry Res; 1994 Sep; 53(3):231-42. PubMed ID: 7870845
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Associations among plasma prolactin levels, tardive dyskinesia, and paranoia in treated schizophrenics: relevance to supersensitivity psychosis.
    Csernansky JG; Vinogradov S; Prosser E; Kaplan J; Berger PA; Hollister LE
    Psychopharmacol Bull; 1986; 22(3):897-9. PubMed ID: 2879311
    [No Abstract]   [Full Text] [Related]  

  • 36. Plasma levels of benperidol, prolactin, and homovanillic acid after intravenous versus two different kinds of oral application of the neuroleptic in schizophrenic patients.
    Seiler W; Wetzel H; Hillert A; Schöllnhammer G; Benkert O; Hiemke C
    Exp Clin Endocrinol; 1994; 102(4):326-33. PubMed ID: 7813605
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neurochemical studies on tardive dyskinesia. I. Urinary homovanillic acid and plasma prolactin.
    Tripodianakis J; Markianos M; Garelis E
    Biol Psychiatry; 1983 Mar; 18(3):337-45. PubMed ID: 6132625
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plasma homovanillic acid in neuroleptic responsive and nonresponsive schizophrenics.
    Duncan E; Wolkin A; Angrist B; Sanfilipo M; Wieland S; Cooper TB; Rotrosen J
    Biol Psychiatry; 1993 Oct; 34(8):523-8. PubMed ID: 8274579
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Growth hormone responses to graded doses of apomorphine HCl in schizophrenia.
    Cleghorn JM; Brown GM; Brown PJ; Kaplan RD; Mitton J
    Biol Psychiatry; 1983 Aug; 18(8):875-85. PubMed ID: 6137249
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Naloxone in chronic schizophrenic patients: neuroendocrine and behavioral effects.
    Kleinman JE; Weinberger DR; Rogol A; Shiling DJ; Mendelson WB; Davis GC; Bunney WE; Wyatt RJ
    Psychiatry Res; 1982 Aug; 7(1):1-7. PubMed ID: 6127744
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.